ZYMEWORKS INC. Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents
ZYMEWORKS INC. (ZYME) reported Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents of $122.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Change in Cash
us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-06
- ZYMEWORKS INC. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2026-03-31 was $98.00K, a 880.00% increase year-over-year.
- ZYMEWORKS INC. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2025-03-31 was $10.00K, a 91.60% decline year-over-year.
- ZYMEWORKS INC. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2024-03-31 was $119.00K, a 65.61% decline year-over-year.
- ZYMEWORKS INC. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2023-03-31 was $346.00K.
- ZYMEWORKS INC. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2025 was -$45.00K, a 115.73% decline from fiscal 2024.
- ZYMEWORKS INC. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2024 was $286.00K, a 19.21% decline from fiscal 2023.
- ZYMEWORKS INC. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2023 was $354.00K, a 74.38% increase from fiscal 2022.
- ZYMEWORKS INC. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2022 was $203.00K.
| Period end | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 3 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 6 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 9 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 12 month |
|---|---|---|---|---|
| 2026-06-30 | $122.00K 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | $98.00K 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | -$45.00K 10-K · filed 2026-03-02 | |||
| 2025-09-30 | -$1.00K 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | -$78.00K 10-Q · filed 2026-08-06 | |||
| 2025-03-31 | $10.00K 10-Q · filed 2026-05-07 | |||
| 2024-12-31 | $286.00K 10-K · filed 2026-03-02 | |||
| 2024-09-30 | $173.00K 10-Q · filed 2025-11-06 | |||
| 2024-06-30 | $181.00K 10-Q · filed 2025-08-07 | |||
| 2024-03-31 | $119.00K 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | $354.00K 10-K · filed 2026-03-02 | |||
| 2023-09-30 | $357.00K 10-Q · filed 2024-10-31 | |||
| 2023-06-30 | $334.00K 10-Q · filed 2024-08-01 | |||
| 2023-03-31 | $346.00K 10-Q · filed 2024-05-02 | |||
| 2022-12-31 | $203.00K 10-K · filed 2025-03-05 | |||
| 2022-09-30 | $291.00K 10-Q · filed 2023-11-07 | |||
| 2022-06-30 | $43.00K 10-Q · filed 2023-08-10 | |||
| 2022-03-31 | -$123.00K 10-Q · filed 2023-05-08 | |||
| 2021-12-31 | -$325.00K 10-K · filed 2024-03-06 | |||
| 2021-09-30 | -$430.00K 10-Q · filed 2022-11-08 | |||
| 2020-12-31 | -$550.00K 10-K · filed 2023-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |